Javascript must be enabled to continue!
Abstract 1781: Ethnic disparity in pediatric leukemia relapse
View through CrossRef
Abstract
Background: Leukemia is the most prevalent pediatric malignancy, representing 25% of all cancer diagnoses among children. Despite recent substantial improvements in therapy that have dramatically increased survival, 10-20% of cases develop relapse and become refractory to treatment. Although racial/ethnic disparity in survival is well documented, limited knowledge currently exists on the disparity in relapse. The objective of this study was to compare the risk of pediatric leukemia relapse between Hispanic Whites and non-Hispanic Whites.
Methods: The study included children (<21 years) diagnosed with leukemia between January 2006 and December 2014 at the All Children's Hospital Johns Hopkins Medicine, St. Petersburg, FL. Patients’ demographic and clinical information were obtained from an electronic health record-derived data warehouse. Ethnicity was self-reported. Leukemia diagnosis and relapse were identified using appropriate ICD-9 codes. Relapse-free survival was defined as the time from diagnosis to the first documentation of relapse. Hazard ratios (HR) and 95% confidence intervals (95% CI) for relapse-free survival were calculated using Cox proportional hazard models adjusting for age at diagnosis, gender and type of insurance (commercial vs government).
Results: The study included 66 Hispanic Whites and 202 non-Hispanic Whites. The median age for both groups was 7 years. However compared to non-Hispanic Whites, Hispanic Whites were more likely to be males (59% vs 53%), to have government insurance (71% vs 35%) and had a shorter median follow up time (52 vs 66 months). Approximately 15% of Hispanic Whites developed relapse compared to only 5% non-Hispanic Whites. Kaplan-Meier survival analysis showed a difference in relapse between the two groups (log-rank p = 0.006). After adjusting for age at diagnosis, gender and type of insurance, Hispanic Whites were three times more likely to develop relapse compared to non-Hispanic Whites (HR = 3.1, 95%CI = 1.2-8.0, p = 0.02).
Conclusion: Although the findings of this study suggest that ethnic disparity in pediatric leukemia may exist, our findings are limited by the inability to control for potential confounders such as medication adherence, timing of diagnosis, white blood cells at diagnosis and minimal residual disease. Future studies should further investigate this racial/ethnic disparity.
Citation Format: Mirinda Gillespie, Greg Hale, Ernest K. Amankwah. Ethnic disparity in pediatric leukemia relapse. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1781.
American Association for Cancer Research (AACR)
Title: Abstract 1781: Ethnic disparity in pediatric leukemia relapse
Description:
Abstract
Background: Leukemia is the most prevalent pediatric malignancy, representing 25% of all cancer diagnoses among children.
Despite recent substantial improvements in therapy that have dramatically increased survival, 10-20% of cases develop relapse and become refractory to treatment.
Although racial/ethnic disparity in survival is well documented, limited knowledge currently exists on the disparity in relapse.
The objective of this study was to compare the risk of pediatric leukemia relapse between Hispanic Whites and non-Hispanic Whites.
Methods: The study included children (<21 years) diagnosed with leukemia between January 2006 and December 2014 at the All Children's Hospital Johns Hopkins Medicine, St.
Petersburg, FL.
Patients’ demographic and clinical information were obtained from an electronic health record-derived data warehouse.
Ethnicity was self-reported.
Leukemia diagnosis and relapse were identified using appropriate ICD-9 codes.
Relapse-free survival was defined as the time from diagnosis to the first documentation of relapse.
Hazard ratios (HR) and 95% confidence intervals (95% CI) for relapse-free survival were calculated using Cox proportional hazard models adjusting for age at diagnosis, gender and type of insurance (commercial vs government).
Results: The study included 66 Hispanic Whites and 202 non-Hispanic Whites.
The median age for both groups was 7 years.
However compared to non-Hispanic Whites, Hispanic Whites were more likely to be males (59% vs 53%), to have government insurance (71% vs 35%) and had a shorter median follow up time (52 vs 66 months).
Approximately 15% of Hispanic Whites developed relapse compared to only 5% non-Hispanic Whites.
Kaplan-Meier survival analysis showed a difference in relapse between the two groups (log-rank p = 0.
006).
After adjusting for age at diagnosis, gender and type of insurance, Hispanic Whites were three times more likely to develop relapse compared to non-Hispanic Whites (HR = 3.
1, 95%CI = 1.
2-8.
0, p = 0.
02).
Conclusion: Although the findings of this study suggest that ethnic disparity in pediatric leukemia may exist, our findings are limited by the inability to control for potential confounders such as medication adherence, timing of diagnosis, white blood cells at diagnosis and minimal residual disease.
Future studies should further investigate this racial/ethnic disparity.
Citation Format: Mirinda Gillespie, Greg Hale, Ernest K.
Amankwah.
Ethnic disparity in pediatric leukemia relapse.
[abstract].
In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA.
Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1781.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
Targeting Genomic Heterogeneity of Adult Acute Lymphoblastic Leukemia
Targeting Genomic Heterogeneity of Adult Acute Lymphoblastic Leukemia
Abstract
Introduction: In acute lymphoblastic leukemia (ALL) genetic diversity at diagnosis has been reported to be correlated with an increased likelihood of emergi...
Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation
Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation
Abstract
Background
Developments in related haploidentical hematopoietic stem cell transplantation (haplo-HSCT) have made two immune systems with inco...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract
Abstract 1606
Introduction:
Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
The Pediatric Anesthesiology Workforce: Projecting Supply and Trends 2015–2035
BACKGROUND:
A workforce analysis was conducted to predict whether the projected future supply of pediatric anesthesiologists is balanced with the requirements of the in...
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
The Geographic Distribution of Pediatric Anesthesiologists Relative to the US Pediatric Population
BACKGROUND:
The geographic relationship between pediatric anesthesiologists and the pediatric population has potentially important clinical and policy implications. In ...
Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Abstract
The evolutionary model of cancer progression suggests that malignant clones survive initial therapy and acquire new mutations, ultimately resulting in thera...

